A new Covid-19 therapy has completed its phase two human trial and the results are promising. Molnupiravir, developed by Ridgeback Biotherapeutics LP and Merck & Co., reached its endpoint objective of ...

In the search for effective COVID-19 treatments, many drugs failed to live up to their early promise. The antiviral molnupiravir performed well in trials, reducing hospitalizations and deaths among ...

As coronavirus cases rage in India, Merck announced that it has entered into non-exclusive voluntary licensing agreements with five manufacturers of generic drugs in that country to speed and expand ...

Almost lost in last week’s blockbuster release of Omicron: Fear and Loathing — The Rise of the Next Variant was an FDA panel’s recommendation that a drug named molnupiravir be given Emergency Use ...

This article is part of a larger series on the risks of molnupiravir. For a summary of the risks at the level of the individual, see here, and for an overview of the risks on a societal level, see ...

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Photo by Martin Sanchez on Unsplash Merck ...

It’s always nice to get some unexpected good news. That’s especially true in COVID World, where the situation (Full hospitals! Thousands of deaths! Protests, stupidity and denial!) always seems ...

A new study suggests that the antiviral Molnupiravir may “paradoxically” be driving COVID-19 mutations, creating variants of concern. What is going on? It is all about molnupiravir’s mode of action ...

After showing a 50% reduction in the risk of hospitalization or death, Merck & Co. and Ridgeback Biotherapeutics’ molnupiravir looks on track to secure an FDA emergency use authorization and become a ...

Last week, Merck and Ridgeback Biotherapeutics announced Phase 3 results of molnupiravir, an oral antiviral drug, in patients with mild-to-moderate Covid-19. In a trial that included more than 750 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The investigational oral antiviral molnupiravir ...

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. The US Food and Drug Administration (FDA) granted emergency use authorization to Merck's antiviral ...